28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials.
Central Drug Research Institute
QSAR analysis of PPAR-gamma agonists as anti-diabetic agents.
Central Drug Research Institute
Antiplasmodial activity of [(aryl)arylsulfanylmethyl]Pyridine.
Central Drug Research Institute
Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives.
Central Drug Research Institute
Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice.
Central Drug Research Institute
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
Central Drug Research Institute
Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents.
Central Drug Research Institute
Aza-annulation on the 16-dehydropregnenolone, via tandem intermolecular aldol process and intramolecular Michael addition.
Central Drug Research Institute
Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.
Central Drug Research Institute
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Central Drug Research Institute
Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents.
Central Drug Research Institute
Synthetic studies in butenonyl C-glycosides: Preparation of polyfunctional alkanonyl glycosides and their enzyme inhibitory activity.
Central Drug Research Institute
Synthesis and biological evaluation of 3,4,6-triaryl-2-pyranones as a potential new class of anti-breast cancer agents.
Central Drug Research Institute
5,6-Diarylanthranilo-1,3-dinitriles as a new class of antihyperglycemic agents.
Central Drug Research Institute
Synthesis of protein tyrosine phosphatase 1B inhibitors: model validation and docking studies.
Central Drug Research Institute
Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.
Central Drug Research Institute
Novel 2-aryl-naphtho[1,2-d]oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities.
Central Drug Research Institute
Rare dipeptide and urea derivatives from roots of Moringa oleifera as potential anti-inflammatory and antinociceptive agents.
Central Drug Research Institute
Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv.
Central Drug Research Institute
Synthesis and QSAR studies on hypotensive 1-[3-(4-substituted phenylthio) propyl]-4-(substituted phenyl) piperazines.
Central Drug Research Institute
Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors.
Central Drug Research Institute
Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents.
Central Drug Research Institute
Synthesis of novel benzofuran isoxazolines as protein tyrosine phosphatase 1B inhibitors.
Central Drug Research Institute
Development of 3D-QSAR models in cyclic ureidobenzenesulfonamides: human beta3-adrenergic receptor agonist.
Central Drug Research Institute
Identification of a potent analogue of Nazumamide A through iteration of combinatorial tetrapeptide libraries.
Central Drug Research Institute
Rational design, synthesis and evaluation of (6aR( *),11bS( *))-1-(4-fluorophenyl)-4-{7-[4-(4-fluorophenyl)-4-oxobutyl]1,2,3,4,6,6a,7,11b,12,12a(RS)-decahydropyrazino[2',1':6,1]pyrido[3,4-b]indol-2-yl}-butan-1-one as a potential neuroleptic agent.
Central Drug Research Institute
